Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
Keyword(s):
2015 ◽
Vol 51
◽
pp. S663
◽
Keyword(s):
2015 ◽
Vol 33
(15_suppl)
◽
pp. 102-102
◽
Keyword(s):
2002 ◽
Vol 20
(6)
◽
pp. 1519-1526
◽
Keyword(s):
2002 ◽
Vol 20
(6)
◽
pp. 1519-1526
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 9011-9011
◽
Keyword(s):
2019 ◽
Vol 37
(7_suppl)
◽
pp. 543-543
◽
Keyword(s):
2007 ◽
Vol 5
(4)
◽
pp. 363
◽
Keyword(s):
Keyword(s):
2018 ◽
Vol 19
(1)
◽
pp. 74-83.e11
◽